Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of “Hold” by Brokerages

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have been assigned a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.00.

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Emergent Biosolutions in a research report on Friday, August 7th. JPMorgan Chase & Co. assumed coverage on Emergent Biosolutions in a report on Friday. They issued an “underweight” rating for the company. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of Emergent Biosolutions stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by company insiders.

Institutional Trading of Emergent Biosolutions

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at approximately $39,525,000. Ancora Advisors LLC purchased a new position in Emergent Biosolutions in the second quarter worth approximately $8,949,000. Millennium Management LLC grew its position in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after acquiring an additional 1,020,582 shares during the period. Palisade Capital Management LP acquired a new stake in Emergent Biosolutions during the second quarter worth $4,316,000. Finally, Jain Global LLC acquired a new stake in Emergent Biosolutions during the third quarter worth $4,487,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Stock Up 5.2%

EBS stock opened at $5.07 on Friday. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. The firm has a 50-day moving average of $7.11 and a two-hundred day moving average of $8.28. Emergent Biosolutions has a 12 month low of $4.36 and a 12 month high of $14.06. The company has a market cap of $259.94 million, a price-to-earnings ratio of -1.43 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. As a group, analysts forecast that Emergent Biosolutions will post -4.63 earnings per share for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.